spot_img
HomeBusinessAcelyrin tanks, rival MoonLake rallies on failed medical trial (SLRN) Receive US

Acelyrin tanks, rival MoonLake rallies on failed medical trial (SLRN) Receive US

Bet_Noire

Acelyrin (NASDAQ:SLRN) inventory tanked in after-hours buying and selling Monday after the corporate mentioned its lead drug izokibep failed a mid-stage medical trial within the remedy of the pores and skin dysfunction hidradenitis suppurativa.

Shares of Acelyrin have been down 64% at $10 at round 5:30 p.m. ET. The

#Acelyrin #tanks #rival #MoonLake #rallies #failed #medical #trial #SLRN

RELATED ARTICLES
Continue to the category

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -spot_img

Most Popular

Recent Comments